patients 1 and 2), trichiasis (patients 2 and 4), and excessive tearing (patient 4). Patient 1 had phimosis that was corrected surgically.Discussion | In our experience using etanercept as treatment for patients with SJS-TEN, including in adults, we have made the following noteworthy observations (although these are only anecdotal). First, we found that a response to treatment with etanercept, namely decreased erythema of existing lesions and halting of progression of new lesions, often occurs 24 to 36 hours after administration. Borrowing from the dosing schedule successfully used in the randomized trial of adults by Wang et al, 5 we recommend considering a second dose in patients who continue to have fevers or notable erythematous and/or edematous skin lesions 36 to 48 hours after the initial dose. Second, patients treated with etanercept demonstrate remarkable time to reepithelialization, which corroborates previous findings comparing etanercept with corticosteroids. 5 Unfortunately this evidence is limited, particularly comparing etanercept with burn-level supportive care. Patient 3 demonstrated a remarkable halting of skin disease. We are not aware of any similar reports of preventing skin denudation in patients with SJS-TEN with early intervention using other immunosuppressive medications. Finally, the lack of adverse events (particularly infections) noted in patients in this series and others is encouraging, although further prospective randomized studies are needed. 4,5

No abstract

In the context of a lack of a gold standard for the diagnosis of neurosyphilis due to either nonspecific or nonsensitive tests, we present in this article a new promising tool highly specific for NS diagnosis. This new test involves measuring an intrathecal synthesis index of specific anti- Treponema IgG by ELISA.

Rare or opportunistic fungal infections are mostly described in immunosuppressed patients. We present a case of a cutaneous phaeohyphomycosis that developed on the dorsal foot in an immunosuppressed woman suffering from AIDS, caused by a novel Phialemoniopsis species. It clinically presented as an indurated violaceous plaque, surmounted by nodules exuding a sero-purulent discharge. A filamentous fungus was isolated from pus and cutaneous biopsy. ITS and LSU sequences phylogenetically resolved the fungus as an unknown species of Phialemoniopsis, which is an unresolved family within Sordariomycetes. In this study we describe the new species as Phialemoniopsis limonesiae, which clusters on a single branch clearly separated from its closest phylogenetic neighbours. This new strain showed low MIC to itraconazole, voriconazole and posaconazole.

Introduction: Enzalutamide (Xtandi®) is a new potent inhibitor of the signaling pathway for the androgen receptor with a half-life of 5.8 days. It has been on the market for the treatment of metastatic castration-resistant prostate cancer since November 2013. Objective:We report the first case of acute generalized exanthematous pustulosis (AGEP) induced by enzalutamide.